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Abstract
Background: The prognostic value of histone γ-H2AX and 53BP1 proteins to predict the radiotherapy (RT) outcome
of patients with rectal carcinoma (RC) was evaluated in a prospective study. High expression of the constitutive
histone γ-H2AX is indicative of defective DNA repair pathway and/or genomic instability, whereas 53BP1 (p53-binding
protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor.
Methods: Using fluorescence microscopy, we assessed spontaneous and radiation-induced foci of γ-H2AX and 53BP1
in peripheral blood mononuclear cells derived from unselected RC patients (n = 53) undergoing neoadjuvant
chemo- and RT. Cells from apparently healthy donors (n = 12) served as references.
Results: The γ-H2AX assay of in vitro irradiated lymphocytes revealed significantly higher degree of DNA damage in
the group of unselected RC patients with respect to the background, initial (0.5 Gy, 30 min) and residual (0.5 Gy and
2 Gy, 24 h post-radiation) damage compared to the control group. Likewise, the numbers of 53BP1 foci analyzed in
the samples from 46 RC patients were significantly higher than in controls except for the background DNA damage.
However, both markers were not able to predict tumor stage, gastrointestinal toxicity or tumor regression after curative
RT. Interestingly, the mean baseline and induced DNA damage was found to be lower in the group of RC patients
with tumor stage IV (n = 7) as compared with the stage III (n = 35). The difference, however, did not reach statistical
significance, apparently, because of the limited number of patients.
Conclusions: The study shows higher expression of γ-H2AX and 53BP1 foci in rectal cancer patients compared with
healthy individuals. Yet the data in vitro were not predictive in regard to the radiotherapy outcome.
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Background
Each year in Germany, about 65 000 people are diagnosed
with the colorectal cancer (CRC) and more than 25 000
people die of the disease [1]. Of those CRC, approximately
one third will be distal to the rectosigmoid junction and
designated as rectal cancer (RC). Patients with locally
advanced RC receive preoperative chemo- and radiation
therapy (RT) in order to reduce the possibility of recur-
rence and to improve survival [2]. However, this depends
on the tumor regression grade (TRG) which strongly
varies between individual patients [3]. A variety of poten-
tial indicators of the success of preoperative chemo- and
RT and among others, p53, EGFR, Ki-67, p21, tumor
oxygenation, immune reaction, and DNA damage re-
sponse etc., are currently studied (for review, see [3, 4]).
However, no reliable marker that can predict patients’
response to curative RT is currently available [3].
DNA damage repair mechanisms serve as a guard
system that protects cells against genetic instability. Both
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genetic instability and impaired DNA damage repair
have been suggested as factors underlying increased sus-
ceptibility to tumorigenesis (for reviews, see [5, 6]). The
significance of genetic instability and impaired DNA re-
pair in tumor development is particularly well proven by
the Ataxia telangiectasia, Fanconi anemia and Nijmegen
breakage syndrome, the diseases also known as chromo-
somal breakage disorders. Indeed, these chromosome
instability syndromes are characterized by defects in
DNA repair, predisposition to different forms of cancer
and increased chemo- and radiation sensitivity (for re-
view, see [7]). Besides these rare diseases, nearly all solid
tumors are genetically unstable [5].
Genomic instability in cancer and DNA repair mecha-
nisms have been analyzed in various population-based
studies using a variety of assays that assess DNA fragmen-
tation by means of the Comet assay, micronucleus test,
chromosomal aberrations, sister chromatid exchanges,
etc. Several of these studies have revealed impaired DNA
repair capacity in peripheral blood mononuclear cells
(PBMCs), exposed in vitro to ionizing radiation (IR) or
UV from breast cancer patients, as evaluated by the
chromosome aberration assay [8–10] as well as by the mi-
cronucleus test [11–13]. In addition, phosphorylation of
histone H2AX can serve as a further valuable marker of
DNA integrity and repair [14]. Constitutive expression of
histone γ-H2AX was suggested to indicate disruption
of the DNA damage repair pathway and/or genetic in-
stability in breast cancer [15]. Moreover, altered expres-
sion of many H2A variants was found to be associated
with cancer [16].
In addition, the kinetics of induction and disappearance
of γ-H2AX foci might be related to the efficiency of
“repair” of higher order chromatin organization [17]. An
impaired DNA repair was found by counting γ-H2AX foci
in blood cells from children with tumors [18]. However,
the initial numbers of γ-H2AX foci after in vitro irradi-
ation were found very similar among the groups studied
[18]. At the same time, Brzozowska et al. (2012) found
by a flow cytometer, an increased expression of his-
tone γ-H2AX in irradiated blood lymphocytes from
normal donors, as compared to tumor patients with
prostate cancer [19]. But the difference was not confirmed
when γ-H2AX foci were counted by fluorescence micros-
copy [19]. Several studies [10, 19–25] evaluated histone γ-
H2AX as a marker to predict the toxicity in normal tissue
during RT of tumor patients, however, with contradictory
conclusions. Some of the quoted studies [19, 21–23]
revealed no correlation between either acute or late side
effects of RT and expression of histone γ-H2AX. However,
other studies [18, 20, 25] found that the loss of histone γ-
H2AX correlated with high-grade toxicity from RT treat-
ment. Henríquez-Hernández et al. (2011) suggest that
lower levels of initial DNA damage may be associated with
a lower risk of suffering from severe late subcutaneous
RT-induced toxicity [24].
Despite numerous studies quoted above into the rela-
tionship between cellular in vitro assays, tumor risk and
clinical RT outcomes, a common opinion has not yet
been made. The controversies cited above prompted us
to evaluate whether the histone γ-H2AX test is able to
predict the clinical RT outcome of RC patients and to
discriminate them from healthy subjects. We examined
both intrinsic and radiation-induced histone γ-H2AX
foci expression in PBMCs from a group of unselected
RC patients (n = 53) and a group of healthy controls
(n = 12). PBMCs from a group (n = 27) of RC patients
with an adverse (grade 2–3) clinical gastro-intestinal
(GI) reaction to RT have also been retrospectively ana-
lyzed. In addition to γ-H2AX, we analyzed the foci of
53BP1 (p53-binding protein 1), a well-known sensor pro-
tein of DNA damage [26]. DNA double-strand breaks
(DSB) attract the 53BP1 protein to the surrounding chro-
matin, where the 53BP1 is recruited by methylated H3
Lys 79 and signals chromatin/DNA damage [26] in a
γ-H2AX-dependent manner.
Methods
Study population and blood selection
The study was performed on PBMCs isolated from two
groups of individuals: (i) a group (n = 53) of unselected
patients with locally advanced RC who were prospect-
ively included in the study and their blood samples were
collected before and after the first 5 clinical radiation
fractions; and (ii) a group of apparently healthy donors
(n = 12), mainly hospital personal. None of the healthy
controls was previously exposed to clinical radiation. All
participants were asked to complete a questionnaire on
their medical histories and lifestyles, including genetic dis-
eases, alcohol consumption and smoking habit (Additional
file 1: Tables S1 and S2). The study was approved by the
Ethics Committee of University of Würzburg and all
patients and donors gave written informed consent.
All recruited RC patients underwent preoperative radio-
chemotherapy treatment at the Department of Radiation
Oncology, University Hospital of Würzburg. Locoregional
tumor stage was evaluated according to the standard UICC
criteria (endoscopy, endorectal ultrasound and MRI) which
resulted in 11, 35, and 7 cases scored as stage II, III, and
IV, respectively (Additional file 1: Tables S1 and S2). All
patients received 3D conformal pelvic irradiation of the
primary tumor and the regional lymphatics by means of a
6 MV linear accelerator (Siemens Concord, CA, USA) at a
dose rate of 2 Gy/min. The regimen comprised 28 fractions
of 1.8 Gy five times a week giving a total dose of 50.4 Gy.
In addition, almost all (98 %) patients received 2 cycles of
5-FU (1000 mg/m2, c.i. 5 days a week) during the 1st and
5th weeks.
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Side effects of RT
Rectal (e.g. proctitis with rectal discomfort, diarrhea or
bleeding) and hematological (e.g. leukocyte counts, plate-
lets and hemoglobin) toxicities due to radio-chemotherapy
were determined during and at the end of the RT accord-
ing to the RTOG [27] and NCI CTCAE v. 4.03 score.
Tumor regression grade (TRG) after chemo- and RT was
determined according to Dworak et al. (1997) and identi-
fied “good” (TRG 3, TRG 4) and “bad” (TRG 0, TRG 1
and TRG 2) responders [28].
Blood sampling and isolation of cells
PBMCs were separated from the heparinized blood
samples by density-gradient centrifugation using Ficoll-
Histopaque 1077 (Sigma 1077–1, Deisenhofen, Germany)
according to the manufacturer's instructions. PBMCs were
washed twice with Ca2+- and Mg2+-free physiological
phosphate-buffered saline (PBS, Sigma D-8537) and finally
resuspended in the RPMI 1640 (Sigma R-8758) supple-
mented with 10 % FBS, glutamine (1 mM), and penicillin-
streptomycin (100 U/ml and 100 μg/ml, respectively),
hereafter denoted as complete growth medium (CGM),
and incubated at 37 °C in a humidified atmosphere
enriched with 5 % CO2 until irradiation.
In vitro X-ray irradiation
The final cell density of isolated G0 unstimulated PBMCs
was adjusted to 1 × 106 cells/ml and the samples were
placed at 37 °C in a 5 % CO2 incubator. X-irradiation (0.5
and 2 Gy) was performed using a 6 MV Siemens linear
accelerator (Siemens Concord, CA, USA) at a dose rate of
2 Gy/min. Non-irradiated cells were treated in similar
way, but at a zero radiation dose.
Immunofluorescence staining for γ-H2AX and 53BP1foci
A cell aliquot (2–3 × 105) of control or irradiated cells
was cytocentrifuged at various time points after IR on a
glass slide and fixed for 15 min in ice-cold methanol,
and then for 1 min in 100 % acetone at −20 °C. Slides were
washed three times for 5 min in PBS and blocked with
4 % FBS-PBS for 1 h at room temperature [29]. Blindly
coded slides were incubated overnight at 4 °C with ei-
ther anti-phospho-histone H2AX (Millipore, Schwalbach,
Germany, # 05–636), or anti-53BP1 (Novus Biologicals,
Cambridge, UK, # NB 100–304) antibodies followed by
incubation with respective secondary antibodies conju-
gated with Alexa Fluor 488 or 594 nm. Slides were
counterstained with 0.2 μg/ml of DAPI (4’,6’-diamidino-2-
phenylindole) in antifade solution (1.5 % N-propyl-gallate,
60 % glycerol in PBS) and examined using a Leica DMLB
epifluorescence microscope (at a 1000x magnification)
coupled to a cooled CCD camera (ColorView 12,
Olympus Biosystems, Hamburg, Germany). Camera con-
trol and image acquisition were done with image analysis
software (Olympus Biosystems, Hamburg, Germany). The
foci were counted by eye in 500 cells per each treatment
condition, no threshold for γ-H2AX or 53BP1 was set.
The cells with apoptotic morphologies or cells with bright
nuclei (intense, complete coverage of the nuclei with foci
staining) were excluded from the analyses. Because the
wide-field microscopic setup used here does not allow
three-dimensional microscopy with Z-planning, two-
dimensional images were captured from the focal plane.
However, in order to detect all foci in the 3D-room we
used the possibility to focus manually through the whole
nucleus. All experiments were counted by one and the
same, trained person.
Statistics
Data are presented as mean (± SE). Mean values were
compared by the Student's t-test or one way ANOVA.
The threshold of statistical significance was set at p < 0.05.
Statistics was performed with the program Origin 8.5
(Microcal, Northampton, MS, USA).
Results
DNA damage and its repair were evaluated up to 24 h
after exposure to 0.5 Gy or 2 Gy of X-rays in vitro or
after 5 first clinical radiation fractions. The extent of
DNA damage was measured by counting the number of
histone γ-H2AX foci, a sensitive marker of DNA DSBs
[30]. The mean data from 500 nuclei were determined
for the cell samples from each tested individual (Fig. 1).
The means for each tested group of individuals are also
shown in Fig. 1.
The parameters on initial, residual and baseline DNA
damage assessed by histone γ-H2AX for each individual,
as well as age, sex, and grade of GI toxicity after RT are
given Fig. 1 and in Additional file 1: Table S3. Although
non-irradiated cells of some RC patients showed remark-
ably lower intrinsic DNA damage, i.e. in the range of
controls, the mean value of background DNA damage
(Fig. 1a) was significantly (p < 0.005) higher (0.5 ± 0.1 foci/
nucleus) in the group of unselected RC patients, as
compared to the group of healthy controls (0.1 ± 0.03).
Likewise, irradiated in vitro blood lymphocytes showed
higher (p < 0.005) initial (Fig. 1b, 0. 5 Gy, 30 min) and
residual (p < 0.005, Fig. 1c and d, 0.5 Gy and 2 Gy, 24 h)
expression of the γ-H2AX foci.
In addition, the foci numbers of 53BP1, a sensor of
DNA damage [26], were compared between 10 healthy
controls and 47 RC patients. As seen in Additional file 1:
Figure S1 and Table S4, the mean background expression
levels of 53BP1 (Additional file 1: Figure S1A) were very
similar in two groups. However, the mean expression of
radiation-induced 53BP1 foci (Additional file 1: Figure S1,
part B) was not significantly higher (3.6 ± 1.8 foci/nucleus)
in the group of RC patients than that in control group
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(2.4 ± 0.4 foci/nucleus) probably because of the enormous
data scattering in the RC group. The numbers of residual
53BP1 foci detected 24 h post-IR (Additional file 1: Figure
S1, parts C and D) were found to be significantly (p < 0.05
and p < 0.005 after 0.5 and 2 Gy, respectively) higher in
the PBMCs derived from RC patients than that of healthy
individuals.
Next, we compared the expression of γ-H2AX and
53BP1 per one and the same nucleus at different time
post-IR and radiation doses. Judging from the correlation
coefficients given in Additional file 1: Figure S2, there was
no (Additional file 1: Figure S2, part A) or weak correlation
(Additional file 1: Figure S2, part B) between background
(0 Gy) or radiation-induced (30 min after irradiation with
0.5 Gy) expression of both proteins, respectively. At the
same time, a strong (R2 = 0.92 and R2 = 0.83) correlation
was found between residual amounts of γ-H2AX and
53BP1 foci (Additional file 1: Figure S2, parts C and D).
Out of 53 prospectively recruited RC patients, 27 exhib-
ited an adverse GI reaction to RT, including grade 2 and
grade 3 according to RTOG score (see Additional file 1:
Table S1). Based on the clinical GI reaction of RT patients
we analyzed retrospectively the initial, residual and
background DNA damage measured by histone γ-H2AX
between the groups of RC patients with normal (RTOG
grade 0 and 1, n = 26) and an adverse (RTOG grade 2
and 3, n = 27) clinical reaction to RT (Fig. 2). As seen
in Fig. 2, background, induced or residual DNA damage in
PBMCs from RC patients with normal or adverse clinical
reaction was higher than that from control donors. How-
ever, there was no difference between the both groups
(grade 0–1 and 2–3) of RC patients in all parameters stud-
ied (Fig. 2a-d). Mostly similar data were obtained with the
53BP1 foci except that there was no difference between
the background numbers of 53BP1 foci counted in all 3
groups (Additional file 1: Figure S3, parts A-D).
Further, we split the group of patients (Fig. 3) with an
adverse GI reaction to RT (grade 2 and 3) into 2 sub-
groups showing either grade 2 (n = 19) or grade 3 (n = 8)
reaction and compared DNA damage between these
groups and a group of normally-reacting (grade 0–1) RC
patients. As seen in Fig. 3, we found no differences in
the baseline, induced or residual DNA damage assessed
by the γ-H2AX foci between the groups.
In addition to the irradiated in vitro cells, as mentioned
in the Methods, blood samples were withdrawn from all
recruited RC patients after 5 clinical fractions. As seen in
Fig. 4a, the mean number of γ-H2AX foci per patient’s
sample after 5 clinical fractions was significantly (p < 0.05)
higher (0.90 ± 0.10) than that before RT (0.55 ± 0.07).
However, the amounts of γ-H2AX foci (1.0 ± 0.3) after
clinical irradiation in a group of RC patients with adverse
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Fig. 1 Comparison of histone γ-H2AX foci in PBMCs derived from control donors and unselected RC patients. a DNA damage assessed by means
of the histone γ-H2AX assay in non-irradiated and b-d in irradiated PBMCs derived from unselected RC patients (triangles), as compared to the
cells from apparently healthy donors (circles). Initial (b), residual (c - 0.5 Gy, 24 h, d - 2 Gy, 24 h) DNA damage were assessed in PBMCs after
irradiation with 0.5 Gy (b, c) or 2 Gy (d) in vitro. Filled squares represent the mean values (± SE) for the respective group
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damage assessed by means of the histone γ-H2AX assay in non-irradiated and b-d irradiated PBMCs derived from normally-reacting RC patients
(grade 0 and 1, up triangles) and radiation-sensitive (grade 2 and 3, down triangles) cancer patients compared to cells from apparently healthy
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were assessed in PBMCs after irradiation either in vitro (b, c) or in vivo (d). Filled squares represent the mean values (± SE) for the respective group.
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triangles, n = 8). Peripheral lymphocytes were prepared from the blood samples derived from RC patients. For details, see legend to Fig. 2
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(grade 3, n = 8) clinical reaction to RT were similar to that
of the unselected (n = 53) RC patients.
The quantification of 53BP1 foci after 5 clinical radi-
ation fractions (Fig. 4b) was conducted in a smaller
group (n = 46 vs. n = 53 tested for γ-H2AX) RC patients,
which however, contained almost all (n = 7) clinically
radiation sensitive RC patients with grade 3 GI reaction
to RT. Comparison of the mean number of 53BP1 foci
per patient’s sample after 5 clinical fractions revealed sig-
nificantly (p < 0.001) increased foci numbers after clinical
irradiation (0.87 ± 0.06 vs. 0.6 ± 0.06 before RT) for the
whole group tested. A subset of clinically irradiated
RC patients with an adverse clinical reaction to RT
showed also an increased but similar number of
53BP1 foci (0.90 ± 0.13) as the group of unselected RC
patients.
Next, we asked whether the tumor stage can influence
the baseline, induced and residual DNA damage in blood
cells of RC patients. We compared the expression of
γ-H2AX and 53BP1 foci in the blood lymphocytes of
RC patients with different UICC tumor stages (Additional
file 1: Table S2). As seen in Fig. 5, no significant difference
in the γ-H2AX foci numbers was observed between tumor
stage II, III or IV. However, the mean number of the back-
ground, induced or residual amount of the γ-H2AX foci
in the group with stage IV has the tendency to be always
lower than that of the group with the tumor stage III.
The same tendency was observed in case of 53BP1
foci (Additional file 1: Figure S4).
In addition, we analyzed if the TRG (Additional file 1:
Table S2) after curative RT can be predicted on the basis
of both protein markers (Fig. 6). Thus we compared the
groups with “bad” (TRG 0–2, n = 34) and “good” (TRG
3–4, n = 19) response to RT. However, we found no dif-
ferences in the background, induced or residual (in vitro
and in vivo) γ-H2AX foci between both groups (Fig. 6).
Likewise, no difference between the groups with “bad”
(TRG 0–2) and “good” (TRG 3–4) response to RT was
observed in the degree of the induction of DNA damage
(Additional file 1: Figure S5).
Discussion
This prospective study was performed to unravel if DNA
damage in peripheral blood lymphocytes can predict RC
patients’ response to combined chemo- und RT or corre-
lated with tumor stage, acute GI toxicity or TRG. Periph-
eral blood cells isolated from (i) unselected RC patients,
and (ii) healthy individuals were analyzed for their DNA
damage using the histone γ-H2AX and 53BP1 assays. The
analysis of non-irradiated as well as irradiated cell samples
revealed significantly higher amounts in the background,
induced and residual DNA damage levels in a group of
unselected RC patients (Fig. 1) compared with healthy
controls. Possible reasons for this can be genetic instability
and impaired DNA repair in the cells derived from tumor
patients. In addition, one of the reasons can be simultan-
eous chemotherapy with 4-FU received by the majority of
RC patients. Yet our results disagree with several studies
[23, 31] who have found no differences in levels of both
basal and radiation-induced DNA damage in cells from
tumor patients with increased clinical radiosensitivity
and healthy controls [23, 31]. The reasons for the dis-
crepancy might reside in the patients’ and controls’ co-
horts, cancer stage, treatment prior to blood sampling,
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Table S2). Up and down triangles show γ-H2AX foci amounts in the cells of RC patients with TRG 0–2 and TRG 3–4, respectively. Filled squares
represent the mean values (± SE) for the respective group. “n.s.” indicates that the difference was not highly significant (p > 0.05)
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arbitrary determined cut-off values, experimental proto-
cols, methods of foci quantification (flow cytometry vs.
fluorescence microscopy) as well as in interlaboratory
variability. Moreover, in contrast to the present and sev-
eral other studies [18, 20, 21, 25], which analyzed primary
PBMCs or T-cells [19], the paper of Vasireddy et al. (2010)
used lymphoblastoid cell lines derived from cells of tumor
patients [23]. Besides this, the quantification of histone γ-
H2AX foci by fluorescence microscopy seems to differ
significantly between laboratories. Thus, the background
values of about 0.07-0.08 γ-H2AX foci per lymphocyte in
non-irradiated cells reported in [21] are some several
times lower than the values presented here in Fig. 1a.
However, our foci counts (4.9 ± 0.4) detected in the sam-
ples from RC patients 30 min after IR with 0.5 Gy corre-
lated well with the numbers (range 6÷14 with a mean of
9.3) published by van Oorschot et al. (2014) 30 min after
irradiation with 1 Gy the lymphocytes derived from pros-
tate cancer patients [32] or with those of Kroeber and
colleagues [33] on 136 RC patients.
Next, the unselected RC patients’ group was split into
the subgroups according to acute gastro-intestinal toxic-
ities (RTOG, see Additional file 1: Table S2), i.e. showing
grade 0–1 and grade 2–3 (Fig. 2). However, retrospective
analysis of RC patients with normal (n = 26) and an
adverse (n = 27) clinical reaction to RT revealed no dif-
ferences in the background (Fig. 2a), induction (Fig. 2b)
and repair (Fig. 2c) of DNA damage 30 min and 24 h
post-IR with 0.5 and 2 Gy in vitro as well as after 5
clinical irradiations (Fig. 2d). Likewise, we found no
differences between normally-reacting and sensitive RT
patients on the base of 53BP1 marker (Additional file 1:
Figure S3). Both tests didn’t allow to identify separately
RC patients with grade 2 and grad 3 toxicities (Fig. 3
and Additional file 1: Figure S3).
In our study the group (an average age of 45 ± 12 years)
of healthy controls was younger than the group of RC
patients (mean age of 66 ± 9 years). The data on age de-
pendence of γ-H2AX expression, however, seems quite
disputable. Thus, based on the comparison of two donor
groups differing markedly in age (31–45 vs. 50–72 years),
Firsanov et al. (2011) conclude that the dynamics of γ-
H2AX induction is independent of age [34]. In contrast,
Sedelnikova et al. (2008) found [35], by comparing two
groups with a much larger deviation (21–30 years vs.
60–72 years) in age than in our study, that the frac-
tions of cells containing γ-H2AX foci in older (60–72
years) individuals was higher (about 30 %) than in youn-
ger individuals (about 20 %). However, the frequency
of γ-H2AX foci in response to IR was found to be
age independent [35].
The second indicator of DNA DSB formation studied
here was the 53BP1 protein. Given that the γ-H2AX test
shows a DSB-induced protein modification and the 53BP1
foci indicate the accumulation of a DSB-modified protein
[26, 36], both types of radiation-induced foci should be
almost overlapping in fluorescence images [37]. In our
hands, however, the 53BP1 assay was less sensitive
than the histone γ-H2AX test in case of endogeneous
(Additional file 1: Figure S1A, 0 Gy) and induced
(Additional file 1: Figure S1B, 0.5 Gy, 30 min) foci. There
may be at least two reasons for the observed discrepancy
between two assays. Firstly, for the detection of γ-H2AX
we used highly specific monoclonal antibodies whereas
the 53BP1 protein was detected with less selective poly-
clonal antibodies. In addition, the 53BP1 foci counting
was done for a smaller patient’s group (n = 46), as com-
pared to γ-H2AX assay (n = 53). Nevertheless, residual
(24 h post-IR) foci of 53BP1 protein were found to be
significantly higher than that from healthy individuals
(Additional file 1: Figure S1, parts C and D).
It is known that a minority (about 5 %) of RT patients
develop either acute or late radiotoxic responses during
or after RT [38]. Among 53 prospectively recruited RC
patients in our study we observed 19 and 8 RC patients
of patients exhibiting early GI radiotoxicity of grade 2
and 3 during RT, respectively. However, we found no
differences in the background, initial and residual DNA
damage between irradiated cells from tumor patients
with normal (Fig. 3, first data set) and those with an
adverse (grade 2 and 3) clinical sensitivity to RT (Fig. 3,
second and third data sets). Likewise, we found no
difference between normally-reacting (grade 0–1) and
radiation-sensitive (grade 3) RC patients after 5 clinical
radiation fractions (Fig. 4).
In addition to GI toxicity to curative RT, we analyzed
whether the γ-H2AX and 53BP1 foci assays allowed to
discriminate between tumor stage (II, III or IV, Fig. 5 and
Additional file 1: Figure S4) or TRG after RT of RC pa-
tients (Fig. 6). However, both markers were not able to
identify either tumor stage or TRG. Interestingly, the
mean baseline, induced and residual DNA damage (Fig. 5)
was found to be somewhat lower in the group of RC
patients with tumor stage IV (n = 7) as compared with the
tumor stage III (n = 35). The difference, however, was
more like a tendency, apparently because of the limited
number of patients, especially with tumor stage IV.
Conclusions
Prospectively recruited RC patients showed on average
increased pre-existing, initial and residual DNA damage
levels measured by histone γ-H2AX and 53BP1 foci, as
compared with the healthy group. However, due to a large
interindividual variability, it was not possible to discrimin-
ate individually RC patients from healthy controls. Neither
it was possible to identify between a minor (n = 8) group
of retrospectively identified RC patients with an adverse
clinical GI reaction of grade 3 to RT and patients with
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grade 2 or normally-reacting RC patients. Likewise, the
assays were not able to recognize tumor stage or to pre-
dict tumor regression grade of RC patients. A larger study
would be necessary in order to investigate the complex
mechanisms behind the normal tissue radiotoxicity and its
correlation with the tumor response to RT.
Additional file
Additional file 1: Table S1. Characteristics of healthy individuals and
RC patients undergoing chemo-radiotherapy (Summary). Table S2. Patients’
characteristics in regard to chemo-radiation toxicities and alcohol/tobacco
consumption. Table S3. DNA damage measured by the histone γ-H2AX in
PBMCs isolated from blood of apparently healthy donors (N) and unselected
rectal carcinoma (RC) patients after exposure to 0.5 or 2 Gy of X-irradiation
in vitro or after 5 clinical radiation fractions. Table S4. DNA damage
measured by the 53BP1 foci in PBMCs isolated from blood of apparently
healthy donors (N) and unselected rectal carcinoma (RC) patients after
exposure to 0.5 or 2 Gy of X-irradiation in vitro or after 5 clinical radiation
fractions. Figure S1. DNA damage assessed by the mean number of
53BP1 foci in non-irradiated (A) and irradiated (B-D) PBMCs derived from
unselected RC patients (triangles), as compared to cells from apparently
healthy donors (circles). For further details, see legend to Fig. 1. Filled
squares represent the mean values (± SE) for the respective group. “n.s.”
indicates that the difference was not highly significant (p > 0.05). Figure S2.
Correlational analysis of mean γ-H2AX and 53BP1 foci counts from 500
nuclei per sample. Non-irradiated (A) and irradiated with 0.5 (B and C)
and 2 Gy (D) lymphocytes were fixed 30 min (B) or 24 h (C, D) post-IR. The
expression of both proteins was analyzed simultaneously at each time and
IR points for n = 48 blood samples derived from unselected RC patients.
Figure S3. DNA damage assessed by means of the 53BP1 assay in non-
irradiated (A) and irradiated (B-D) PBMCs derived from normally-reacting RC
patients (grade 0 and 1, up triangles) and radiation-sensitive (grade 2 and 3,
down triangles) cancer patients compared to cells from apparently healthy
donors (circles). Filled squares represent the mean values (± SE) for the
respective group. For details, see legend to Fig. 2. Figure S4. Correlation
between the 53BP1 foci expression and tumor staging (see Additional file 1:
Table S2). Peripheral lymphocytes were prepared from the blood samples
derived from RC patients. Foci counting for 53BP1 were performed in
non-irradiated (A), irradiated in vitro with 0.5 and 2 Gy samples 30 min
and 24 h post-IR (B and C) or 72 h after 5 clinical radiation fractions (D).
Filled squares represent the mean values (± SE) for the respective group.
Figure S5. Comparison of the γ-H2AX foci expression in peripheral
lymphocytes of RC patients differing in tumor regression grade (TRG,
Additional file 1: Table S2). Foci counting for γ-H2AX were performed in
non-irradiated (up triangles and circles) cells or after 5 clinical radiation
fractions (down triangles and diamonds). Filled squares represent the mean
values (± SE) for the respective group. (DOC 1915 kb)
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